CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) used in laboratory research into the endocrine pathways that regulate growth hormone. It appears widely in preclinical literature examining how GHRH receptor signalling influences pulsatile hormone release.
What is CJC-1295?
CJC-1295 is a modified peptide based on the first 29 amino acids of naturally occurring GHRH — the fragment responsible for receptor binding. Several amino acid substitutions were introduced to slow enzymatic breakdown, which is the principal limitation of native GHRH in experimental settings, where it degrades within minutes.
The compound exists in two distinct research forms. One incorporates a Drug Affinity Complex (DAC) that extends its presence in circulation considerably. The other omits it, and is frequently listed as CJC-1295 without DAC, or Modified GRF (1-29). The difference is substantial enough that the two are not interchangeable in study design, and we cover it in detail in our companion article on CJC-1295 with DAC versus without DAC.
How is it studied?
Research interest centres on the GHRH receptor, found on somatotroph cells of the anterior pituitary. Laboratory investigation typically examines how binding at this receptor influences the release of endogenous growth hormone, and how that release pattern differs from direct hormone administration.
A recurring theme in the literature is that GHRH analogues appear to amplify the body’s own signalling rather than replace it, meaning existing feedback mechanisms remain in play. This makes them useful tools for studying regulatory control rather than simply elevating hormone levels.
Why is it grouped with secretagogues?
CJC-1295 belongs to the broader class of growth hormone secretagogues. Within that class it acts on the GHRH receptor, while others — the ghrelin mimetics such as Ipamorelin and the GHRPs — act on an entirely separate receptor. Researchers frequently examine the two pathways together precisely because they are distinct.
Handling and stability
Like most research peptides, CJC-1295 is supplied as a lyophilised powder and must be reconstituted before laboratory use. Reconstituted solutions have a considerably shorter stability window than the freeze-dried form, and repeated freeze-thaw cycles degrade peptide structure. Our Reconstitution & Storage guide covers general laboratory practice, including calculators for concentration and stability.
Verifying what you have
Peptide identity and purity cannot be assessed by eye. Analytical verification — typically HPLC for purity and mass spectrometry for identity — is what distinguishes a characterised research compound from an unknown powder. See why Certificates of Analysis matter.
Availability
We supply both forms for laboratory research: CJC-1295 Without DAC 5mg and CJC-1295 With DAC 5mg.
For Research Use Only. Not for Human Consumption. This article is provided for laboratory research and educational purposes only. It does not constitute medical advice, and no dosing or administration guidance is offered or implied. Products supplied by Qube Peptides are not medicines, are not dietary supplements, and are not intended for human or veterinary use.
